Recombinant human endostatin could eliminate the pro-angiogenesis priority of SP cells sorted from non-small cell lung cancer cells

详细信息    查看全文

• 作者：Baoshan Cao (1)
  Jun Jia (2)
  Liwen Ma (1)
  Lijun Di (2)
  Guohong Song (2)
  Yanhua Yuan (2)
  Bo Ma (2)
  Yulin Zhu (2)
  Jing Yu (2)
  Xiaoli Wang (2)
  Xinna Zhou (2)
  H. Kim Lyerly (3)
  Jun Ren (2) (4)
  
• 关键词：Non ; small cell lung cancer ; Side population ; Angiogenesis
• 刊名：Clinical and Translational Oncology
• 出版年：2012
• 出版时间：August 2012
• 年：2012
• 卷：14
• 期：8
• 页码：575-585
• 全文大小：820KB
• 参考文献：1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55(2):74-08 CrossRef
  2. Collins LG, Haines C, Perkel R, Enck RE (2007) Lung cancer: diagnosis and management. Am Fam Phys 75(1):56-3
  3. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106-30 CrossRef
  4. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and cancer stem cells. Nature 414(6859):105-11 CrossRef
  5. Pardal R, Clarke MF, Morrison SJ (2003) Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3(12):895-02 CrossRef
  6. Beachy PA, Karhadkar SS, Berman DM (2004) Tissue repair and stem cell renewal in carcinogenesis. Nature 432(7015):324-31 CrossRef
  7. Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK, Andreeff M, Goodell MA (2001) A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98(4):1166-173 CrossRef
  8. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367(6464):645-48 CrossRef
  9. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983-988 CrossRef
  10. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, Kornblum HI (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 100(25):15178-5183 CrossRef
  11. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB (2004) Identification of human brain tumour initiating cells. Nature 432(7015):396-01 CrossRef
  12. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC (1996) Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183(4):1797-806 CrossRef
  13. Ho MM, Ng AV, Lam S, Hung JY (2007) Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67(10):4827-833 CrossRef
  14. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82(1):4- CrossRef
  15. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407(6801):242-48 CrossRef
  16. Ferrara N (1999) Molecular and biological properties of vascular endothelial growth factor. J Mol Med (Berlin) 77(7):527-43 CrossRef
  17. Reck M, von Pawel J, Zatloukal P, Ramlau R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, Manegold C (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 27(8):1227-234 CrossRef
  18. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542-550 CrossRef
  19. Folkman J (2006) Antiangiogenesis in cancer therapy—endostatin and its mechanisms of action. Exp Cell Res 312(5):594-07 CrossRef
  20. Yang L, Wang JW, Sun Y, Zhu YZ, Liu XQ, Li WL, Di LJ, Li PW, Wang YL, Song SP, Yao C, You LF (2006) Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 28(2):138-41
  21. Huang C, Wang LC, Xiao JY, Ye ZX, Liu ZJ, Xu WJ, Cheng X, Wang J, Li K (2008) Analysis of cavitation of advanced NSCLC treated by rh-endostatin combined with NP chemotherapy. Zhonghua Zhong Liu Za Zhi 30(9):712-15
  22. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66(16):7843-848 CrossRef
  23. Bjerkvig R, Johansson M, Miletic H, Niclou SP (2009) Cancer stem cells and angiogenesis. Semin Cancer Biol 19(5):279-84 CrossRef
  24. Zhao Y, Bao Q, Renner A, Camaj P, Eichhorn M, Ischenko I, Angele M, Kleespies A, Jauch KW, Bruns C (2011) Cancer stem cells and angiogenesis. Int J Dev Biol 55(4-):477-82 CrossRef
  25. Ling Y, Yang Y, Lu N, You QD, Wang S, Gao Y, Chen Y, Guo QL (2007) Endostar, a novel recombinant human endostatin, exerts antiangiogenic effect via blocking VEGF-induced tyrosine phosphorylation of KDR/Flk-1 of endothelial cells. Biochem Biophys Res Commun 361(1):79-4 CrossRef
  26. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445(7123):111-15 CrossRef
  27. O’Brien CA, Pollett A, Gallinger S, Dick JE (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445(7123):106-10 CrossRef
  28. Kondo T, Setoguchi T, Taga T (2004) Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 101(3):781-86 CrossRef
  29. Sung JM, Cho HJ, Yi H, Lee CH, Kim HS, Kim DK, Abd El-Aty AM, Kim JS, Landowski CP, Hediger MA, Shin HC (2008) Characterization of a stem cell population in lung cancer A549 cells. Biochem Biophys Res Commun 371(1):163-67 CrossRef
  30. Seo DC, Sung JM, Cho HJ, Yi H, Seo KH, Choi IS, Kim DK, Kim JS, El-Aty AA, Shin HC (2007) Gene expression profiling of cancer stem cell in human lung adenocarcinoma A549 cells. Mol Cancer 6:75 CrossRef
  31. Hirschmann-Jax C, Foster AE, Wulf GG, Nuchtern JG, Jax TW, Gobel U, Goodell MA, Brenner MK (2004) A distinct “side population-of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101(39):14228-4233 CrossRef
  32. Oklu R, Walker TG, Wicky S, Hesketh R (2010) Angiogenesis and current antiangiogenic strategies for the treatment of cancer. J Vasc Interv Radiol 21(12):1791-805; quiz 806
  33. Cook KM, Figg WD (2010) Angiogenesis inhibitors: current strategies and future prospects. CA Cancer J Clin 60(4):222-43 CrossRef
  34. Tang CH, Tan TW, Fu WM, Yang RS (2008) Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis. Carcinogenesis 29(1):35-3 CrossRef
  35. Petit I, Jin D, Rafii S (2007) The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 28(7):299-07 CrossRef
  36. Liang Z, Brooks J, Willard M, Liang K, Yoon Y, Kang S, Shim H (2007) CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun 359(3):716-22 CrossRef
  37. Fontanini G, Boldrini L, Chine S, Pisaturo F, Basolo F, Calcinai A, Lucchi M, Mussi A, Angeletti CA, Bevilacqua G (1999) Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas. Br J Cancer 79(2):363-69 CrossRef
  38. Fontanini G, Faviana P, Lucchi M, Boldrini L, Mussi A, Camacci T, Mariani MA, Angeletti CA, Basolo F, Pingitore R (2002) A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer 86(4):558-63 CrossRef
  39. Gridelli C, Rossi A, Maione P (2006) New antiangiogenetic agents and non-small cell lung cancer. Crit Rev Oncol Hematol 60(1):76-6 CrossRef
  40. Monzani E, Facchetti F, Galmozzi E, Corsini E, Benetti A, Cavazzin C, Gritti A, Piccinini A, Porro D, Santinami M, Invernici G, Parati E, Alessandri G, La Porta CA (2007) Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 43(5):935-46 CrossRef
  41. Li C, Lee CJ, Simeone DM (2009) Identification of human pancreatic cancer stem cells. Methods Mol Biol 568:161-73 CrossRef
  42. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, Conticello C, Ruco L, Peschle C, De Maria R (2008) Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 15(3):504-14 CrossRef
  43. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE (2004) CEACAM6 gene silencing impairs anoikis resistance and in vivo metastatic ability of pancreatic adenocarcinoma cells. Oncogene 23(2):465-73 CrossRef
  44. Duxbury MS, Ito H, Benoit E, Waseem T, Ashley SW, Whang EE (2004) A novel role for carcinoembryonic antigen-related cell adhesion molecule 6 as a determinant of gemcitabine chemoresistance in pancreatic adenocarcinoma cells. Cancer Res 64(11):3987-993 CrossRef
  45. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, Sorrentino BP (2001) The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7(9):1028-034 CrossRef
  46. Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD, Sorrentino BP (2002) Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci USA 99(19):12339-2344 CrossRef
  47. Eaker SS, Hawley TS, Ramezani A, Hawley RG (2004) Detection and enrichment of hematopoietic stem cells by side population phenotype. Methods Mol Biol 263:161-80
  
• 作者单位：Baoshan Cao (1)
  Jun Jia (2)
  Liwen Ma (1)
  Lijun Di (2)
  Guohong Song (2)
  Yanhua Yuan (2)
  Bo Ma (2)
  Yulin Zhu (2)
  Jing Yu (2)
  Xiaoli Wang (2)
  Xinna Zhou (2)
  H. Kim Lyerly (3)
  Jun Ren (2) (4)
  
  1. Department of Oncology, Peking University Third Hospital, Beijing, 100191, China
  2. Department of Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Beijing Cancer Hospital and Institute, Peking University School of Oncology, 52 Fucheng Rd, Beijing, 100142, China
  3. Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, NC, 27710, USA
  4. Capital Medical University, Beijing Shijitan Hospital, 10 Tieyilu, Beijing, 100038, China
  

文摘

Purpose To ascertain the biologic significance of lung cancer Side population (SP) cells, which represent putative cancer stem cells (CSC) in the absence of consensus biomarkers for tumor-specific CSC. Materials and methods We sorted and analyzed the angiogenic features of SP cells, isolated from tumor cell lines based on the exclusion of the DNA dye Hoechst 33342, from the NSCLC cell lines A549 and H460. Results Compared with non-SP cells, mRNA of vascular endothelial growth factor (VEGF)-A, VEGF-B, angiopoietin (ang)-1, ang-2, fibroblast growth factor-2 (FGF-2), cyclooxygenase-2 (Cox-2) and interleukin-8 (IL-8) were over-expressed in SP cells accompanied by over-expression of ABCG2 and MDR1 mRNA. The supernatant of cultured SP cells could significantly induce migration of human umbilical vein endothelial cells, while recombinant human endostatin (Endostar 25?) could inhibit the migration. Conclusions This study revealed that the NSCLC SP cells might represent CSCs and possess pro-angiogenic properties, and antiangiogenesis represent a potential therapy.